Investigating the connection between MYC and SWI/SNF in aggressive pediatric tumors
The MYC-SWI/SNF connection in rhabdoid tumors
['FUNDING_R01'] · VANDERBILT UNIVERSITY · NIH-10853009
This study is looking at how a missing protein called SMARCB1 helps cause rare and aggressive cancers in kids, called rhabdoid tumors, and aims to find new ways to treat these tumors by understanding how it interacts with another protein, c-MYC.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-10853009 on ClinicalTrials.gov |
What this research studies
This research focuses on rhabdoid tumors, which are rare and aggressive cancers primarily affecting children. The study aims to understand how the loss of a specific tumor suppressor, SMARCB1, leads to the development of these tumors by activating a protein called c-MYC. By exploring the molecular mechanisms involved, the research seeks to identify potential therapeutic targets that could improve treatment options for affected children. The approach includes examining the interactions between MYC and chromatin remodeling components to uncover new strategies for intervention.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with rhabdoid tumors, particularly those who have limited treatment options.
Not a fit: Patients with other types of cancers or those who do not have rhabdoid tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that significantly improve survival rates for children diagnosed with rhabdoid tumors.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in other cancers, suggesting potential for success in this novel approach.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TANSEY, WILLIAM PATRICK — VANDERBILT UNIVERSITY
- Study coordinator: TANSEY, WILLIAM PATRICK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer